Validating intramyocardial bone marrow stem cell therapy in combination with coronary artery bypass grafting, the PERFECT Phase III randomized multicenter trial: study protocol for a randomized controlled trial

Trials

Gustav Steinhoff²  Guenther Kundt¹  Gudrun Tiedemann²  Alexander Kaminski²  Peter Donndorf² 

[1] Institute for Biostatistics and Informatics in Medicine and Ageing Research, University of Rostock, Rostock, Germany;Department of Cardiac Surgery, Reference and Translation Centre for Cardiac Stem cell therapy, University of Rostock, Schillingallee 35, Rostock, 18057, Germany

关键词: Stem cell;    Trial;    Ischemic heart disease;    Intramyocardial;    CABG;   

Others  :  1095501
DOI  :  10.1186/1745-6215-13-99

 received in 2012-01-18, accepted in 2012-07-02,  发布年份 2012

【 摘 要 】

Background

For the last decade continuous efforts have been made to translate regenerative cell therapy protocols in the cardiovascular field from ‘bench to bedside’. Successful clinical introduction, supporting safety, and feasibility of this new therapeutic approach, led to the initiation of the German, Phase III, multicenter trial - termed the PERFECT trial (ClinicalTrials.gov Identifier: NCT00950274), in order to evaluate the efficacy of surgical cardiac cell therapy on left ventricular function.

Methods/Design

The PERFECT trial has been designed as a prospective, randomized, double-blind, placebo controlled, multicenter trial, analyzing the effect of intramyocardial CD 133⁺ bone marrow stem cell injection in combination with coronary artery bypass grafting on postoperative left ventricular function. The trial includes patients aged between 18 and 79 years presenting with a coronary disease with indication for surgical revascularization and reduced global left ventricular ejection fraction as assessed by cardiac magnet resonance imaging. The included patients are treated in the chronic phase of ischemic cardiomyopathy after previous myocardial infarction.

Discussion

Patients undergoing coronary artery bypass grafting in combination with intramyocardial CD133⁺ cell injection will have a higher LV ejection fraction than patient who undergo CABG alone, measured 6 months after the operation.

Trial registration

ClinicalTrials.gov Identifier: NCT00950274

【 授权许可】

   
2012 Donndorf et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P: Bone marrow cells regenerate infarcted myocardium. Nature 2001, 410:701-705.
• [2]Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, Entman ML, Michael LH, Hirschi KK, Goodell MA: Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001, 107:1395-1402.
• [3]Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, Kogler G, Wernet P: Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002, 106:1913-1918.
• [4]Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H, Schumichen C, Nienaber CA, Freund M, Steinhoff G: Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003, 361:45-46.
• [5]Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, Zupicich J, Alkass K, Buchholz BA, Druid H, Jovinge S, Frisen J: Evidence for cardiomyocyte renewal in humans. Science 2009, 324:98-102.
• [6]Ma N, Ladilov Y, Kaminski A, Piechaczek C, Choi YH, Li W, Steinhoff G, Stamm C: Umbilical cord blood cell transplantation for myocardial regeneration. Transplant Proc 2006, 38:771-773.
• [7]Kaminski A, Steinhoff G: Current status of intramyocardial bone marrow stem cell transplantation. Semin Thorac Cardiovasc Surg 2008, 20:119-125.
• [8]Stamm C, Kleine HD, Choi YH, Dunkelmann S, Lauffs JA, Lorenzen B, David A, Liebold A, Nienaber C, Zurakowski D, Freund M, Steinhoff G: Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J Thorac Cardiovasc Surg 2007, 133:717-725.
• [9]Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM: Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006, 355:1210-1221.
• [10]Donndorf P, Kundt G, Kaminski A, Yerebakan C, Liebold A, Steinhoff G, Glass A: Intramyocardial bone marrow stem cell transplantation during coronary artery bypass surgery: a meta-analysis. J Thorac Cardiovasc Surg 2011, 142:911-920.
• [11]Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, Zuba-Surma EK, Al-Mallah M, Dawn B: Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007, 167:989-997.
• [12]Horst KW: Stem cell therapy for myocardial infarction: are we missing time? Cardiology 2010, 117:1-10.
• [13]Nasseri BA, Kukucka M, Dandel M, Knosalla C, Choi YH, Ebell W, Hetzer R, Stamm C: Two-dimensional speckle tracking strain analysis for efficacy assessment of myocardial cell therapy. Cell Transplant 2009, 18:361-370.